RIVA-DM: Effectiveness and Safety of Rivaroxaban vs. Warfarin in Nonvalvular Atrial Fibrillation and Diabetes Mellitus: Analysis of Electronic Health Record Data
Latest Information Update: 22 Sep 2021
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism; Stroke; Thrombosis
- Focus Therapeutic Use
- Acronyms RIVA-DM
- Sponsors Bayer
- 08 Sep 2021 Status changed from active, no longer recruiting to completed.
- 18 Jun 2021 Planned End Date changed from 31 May 2021 to 31 Jul 2021.
- 18 Jun 2021 Planned primary completion date changed from 31 May 2021 to 31 Jul 2021.